Envestnet Asset Management
ALLO icon

Envestnet Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Envestnet Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,602
Closed -$23.1K – 4455
2025
Q3 		$23.1K Sell
18,602
-424
-2% -$505 ﹤0.01% 4494
2025
Q2 		$21.5K Sell
19,026
-269
-1% -$357 ﹤0.01% 4409
2025
Q1 		$28.2K Sell
19,295
-1,794
-9% -$3.38K ﹤0.01% 4322
2024
Q4 		$44.9K Buy
21,089
+5,490
+35% +$13.5K ﹤0.01% 4267
2024
Q3 		$43.7K Buy
15,599
+1,638
+12% +$4.37K ﹤0.01% 4184
2024
Q2 		$32.5K Buy
13,961
+1,634
+13% +$4.82K ﹤0.01% 4127
2024
Q1 		$55.1K Buy
+12,327
New +$51.4K ﹤0.01% 4101
2021
Q4 		– Sell
-15,191
Closed -$390K – 3867
2021
Q3 		$390K Sell
15,191
-62
-0.4% -$1.47K ﹤0.01% 3126
2021
Q2 		$398K Buy
15,253
+65
+0.4% +$1.85K ﹤0.01% 3112
2021
Q1 		$536K Buy
+15,188
New +$512K ﹤0.01% 2803

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Envestnet Asset Management's ALLO Position: Q4 2025 in Review

Envestnet Asset Management sold out of Allogene Therapeutics (ALLO) in Q4 2025, closing a stake of 18,602 shares — an estimated $23.1K sold.

Envestnet Asset Management first reported a position in ALLO in Q1 2021 and held it in 10 quarters. The position peaked at $536K in Q1 2021. 172 funds tracked by Wall St. Rank hold ALLO as of Q4 2025.

  • Envestnet Asset Management reported no remaining Allogene Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 18,602 Allogene Therapeutics shares in Q4 2025, an estimated $23.1K.
  • Envestnet Asset Management first reported a position in Allogene Therapeutics in Q1 2021 and held it in 10 quarters.
  • Envestnet Asset Management's Allogene Therapeutics position peaked at $536K in Q1 2021.
  • 172 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2025.

Based on Envestnet Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.